Marian Salatino
  • Immunopathology Department, Institute of Biology and Experimental Medicine, CONICET, Argentina
Research fields
  • Cancer biology
Personal information


Ph.D., University of Buenos Aires, Argentina, 2007

Current position

Associate Research CONICET, Laboratory of Immunopathology, Institute of Biology and Ex-perimental Medi¬cine, Buenos Aires, Argentina


  1. Croci, D. O., Cerliani, J. P., Dalotto-Moreno, T., Mendez-Huergo, S. P., Mascanfroni, I. D., Dergan-Dylon, S., Toscano, M. A., Caramelo, J. J., Garcia-Vallejo, J. J., Ouyang, J., Mesri, E. A., Junttila, M. R., Bais, C., Shipp, M. A., Salatino, M. and Rabinovich, G. A. (2014). Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors. Cell 156(4): 744-758.
  2. Spallanzani, R. G., Dalotto-Moreno, T., Raffo Iraolagoitia, X. L., Ziblat, A., Domaica, C. I., Avila, D. E., Rossi, L. E., Fuertes, M. B., Battistone, M. A., Rabinovich, G. A., Salatino, M. and Zwirner, N. W. (2013). Expansion of CD11b+ Ly6G+ Ly6C int cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions. Cancer Immunol Immunother 62(12): 1781-1795.
  3. Salatino, M., Dalotto-Moreno, T. and Rabinovich, G. A. (2013). Thwarting galectin-induced immunosuppression in breast cancer. Oncoimmunology 2(5): e24077.
  4. Dalotto-Moreno, T., Croci, D. O., Cerliani, J. P., Martinez-Allo, V. C., Dergan-Dylon, S., Mendez-Huergo, S. P., Stupirski, J. C., Mazal, D., Osinaga, E., Toscano, M. A., Sundblad, V., Rabinovich, G. A. and Salatino, M. (2013). Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73(3): 1107-1117.
  5. Croci, D. O., Salatino, M., Rubinstein, N., Cerliani, J. P., Cavallin, L. E., Leung, H. J., Ouyang, J., Ilarregui, J. M., Toscano, M. A., Domaica, C. I., Croci, M. C., Shipp, M. A., Mesri, E. A., Albini, A. and Rabinovich, G. A. (2012). Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 209(11): 1985-2000.
  6. Zacarias Fluck, M. F., Hess, L., Salatino, M., Croci, D. O., Stupirski, J. C., Di Masso, R. J., Roggero, E., Rabinovich, G. A. and Scharovsky, O. G. (2012). The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide. Cancer Immunol Immunother 61(4): 469-480.
  7. Soldati, R., Berger, E., Zenclussen, A. C., Jorch, G., Lode, H. N., Salatino, M., Rabinovich, G. A. and Fest, S. (2012). Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer 131(5): 1131-1141.
  8. Maldonado, C. A., Sundblad, V., Salatino, M., Elia, J., Garcia, L. N., Leimgruber, C., Croci, D. O. and Rabinovich, G. A. (2011). Cell-type specific regulation of galectin-3 expression by glucocorticoids in lung Clara cells and macrophages. Histol Histopathol 26(6): 747-759.
  9. Croci, D. O. and Salatino, M. (2011). Tumor immune escape mechanisms that operate during metastasis. Curr Pharm Biotechnol 12(11): 1923-1936.
  10. Salatino, M. and Rabinovich, G. A. (2011). Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview. Methods Mol Biol 677: 355-374.
  11. Laderach, D. J., Compagno, D., Toscano, M. A., Croci, D. O., Dergan-Dylon, S., Salatino, M. and Rabinovich, G. A. (2010). Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings. IUBMB Life 62(1): 1-13.
  12. Ilarregui, J. M., Croci, D. O., Bianco, G. A., Toscano, M. A., Salatino, M., Vermeulen, M. E., Geffner, J. R. and Rabinovich, G. A. (2009). Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10(9): 981-991.
  13. Salatino, M., Croci, D. O., Bianco, G. A., Ilarregui, J. M., Toscano, M. A. and Rabinovich, G. A. (2008). Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin Biol Ther 8(1): 45-57.
  14. Rivas, M. A., Carnevale, R. P., Proietti, C. J., Rosemblit, C., Beguelin, W., Salatino, M., Charreau, E. H., Frahm, I., Sapia, S., Brouckaert, P., Elizalde, P. V. and Schillaci, R. (2008). TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res 314(3): 509-529.
  15. Carnevale, R. P., Proietti, C. J., Salatino, M., Urtreger, A., Peluffo, G., Edwards, D. P., Boonyaratanakornkit, V., Charreau, E. H., Bal de Kier Joffe, E., Schillaci, R. and Elizalde, P. V. (2007). Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 21(6): 1335-1358.
  16. Toscano, M. A., Ilarregui, J. M., Bianco, G. A., Campagna, L., Croci, D. O., Salatino, M. and Rabinovich, G. A. (2007). Dissecting the pathophysiologic role of endogenous lectins: glycan-binding proteins with cytokine-like activity? Cytokine Growth Factor Rev 18(1-2): 57-71.
  17. Daroqui, C. M., Ilarregui, J. M., Rubinstein, N., Salatino, M., Toscano, M. A., Vazquez, P., Bakin, A., Puricelli, L., Bal de Kier Joffe, E. and Rabinovich, G. A. (2007). Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol Immunother 56(4): 491-499.
  18. Salatino, M., Beguelin, W., Peters, M. G., Carnevale, R., Proietti, C. J., Galigniana, M. D., Vedoy, C. G., Schillaci, R., Charreau, E. H., Sogayar, M. C. and Elizalde, P. V. (2006). Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene 25(59): 7723-7739.
  19. Schillaci, R., Salatino, M., Cassataro, J., Proietti, C. J., Giambartolomei, G. H., Rivas, M. A., Carnevale, R. P., Charreau, E. H. and Elizalde, P. V. (2006). Immunization with murine breast cancer cells treated with antisense oligodeoxynucleotides to type I insulin-like growth factor receptor induced an antitumoral effect mediated by a CD8+ response involving Fas/Fas ligand cytotoxic pathway. J Immunol 176(6): 3426-3437.
  20. Proietti, C., Salatino, M., Rosemblit, C., Carnevale, R., Pecci, A., Kornblihtt, A. R., Molinolo, A. A., Frahm, I., Charreau, E. H., Schillaci, R. and Elizalde, P. V. (2005). Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 25(12): 4826-4840.
  21. Salatino, M., Schillaci, R., Proietti, C. J., Carnevale, R., Frahm, I., Molinolo, A. A., Iribarren, A., Charreau, E. H. and Elizalde, P. V. (2004). Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 23(30): 5161-5174.
  22. Labriola, L., Salatino, M., Proietti, C. J., Pecci, A., Coso, O. A., Kornblihtt, A. R., Charreau, E. H. and Elizalde, P. V. (2003). Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol 23(3): 1095-1111.
  23. Puricelli, L., Proietti, C. J., Labriola, L., Salatino, M., Balana, M. E., Aguirre Ghiso, J., Lupu, R., Pignataro, O. P., Charreau, E. H., Bal de Kier Joffe, E. and Elizalde, P. V. (2002). Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Int J Cancer 100(6): 642-653.
  24. Salatino, M., Labriola, L., Schillaci, R., Charreau, E. H. and Elizalde, P. V. (2001). Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors. Exp Cell Res 265(1): 152-166.
  25. Balana, M. E., Labriola, L., Salatino, M., Movsichoff, F., Peters, G., Charreau, E. H. and Elizalde, P. V. (2001). Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20(1): 34-47.
  26. Viegas, M. H., Salatino, M., Goin, M., Peters, G., Labriola, L., Costa da cunha, J., Lanari, C., Charreau, E. H. and Elizalde, P. V. (1999). Differential expression of and responsiveness to transforming growth factor-beta (TGF-beta) isoforms in hormone-dependent and independent lines of mouse mammary tumors. Cancer Detect Prev 23(5): 375-386.
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.